PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28166200-7	2017	Following knockdown of MARCKS in RCC cells, the IC50 of the multikinase inhibitor regorafenib was reduced.	regorafenib	82-93	myristoylated alanine rich protein kinase C substrate	Homo sapiens	23-29	
28166200-8	2017	Surprisingly, attenuation of MARCKS using the MPS (MARCKS phosphorylation site domain) peptide synergistically interacted with regorafenib treatment and decreased survival of kidney cancer cells through inactivation of AKT and mTOR.	regorafenib	127-138	myristoylated alanine rich protein kinase C substrate	Homo sapiens	29-35	
28166200-8	2017	Surprisingly, attenuation of MARCKS using the MPS (MARCKS phosphorylation site domain) peptide synergistically interacted with regorafenib treatment and decreased survival of kidney cancer cells through inactivation of AKT and mTOR.	regorafenib	127-138	myristoylated alanine rich protein kinase C substrate	Homo sapiens	51-57